• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Scott T. Tagawa on PSMA-targeted agents in prostate cancer


Scott T. Tagawa, MD, discusses the emergence of PSMA-targeted agents in the field of prostate cancer. He draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617 (LuPSMA) and the phase 2 TheraP trial, which showed that LuPSMA had stronger clinical activity with fewer grade 3/4 adverse events compared with cabazitaxel (Jevtana) in patients with metastatic castration-resistant prostate cancer (mCRPC). Subsequent to this interview, it was announced that in the phase 3 VISION trial, adding LuPSMA to best standard of care improved overall survival in patients with progressive PSMA-positive mCRPC.

Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.

Related Videos
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Prostate cancer cell division | Image Credit: © PRB ARTS - stock.adobe.com
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.